The invention relates to a method of treating AML in a subject having a white blood cell (WBC) count of less than about 10,000 cells/microliter, and/or a cytogenetic risk classification according to the US Southwest Oncology Group (SWOG) that is not unfavourable, and/or the subject falls within a classification selected from antecedent myelodysplastic syndrome (MDS), antecedent myeloproliferative neoplasm (MPN), and antecedent myelodysplastic/myeloproliferative neoplasm (MDS/MPN), wherein the method comprises (i) a first treatment cycle comprising administering decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer； and (ii) a second treatment cycle comprising administering sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer.
